Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Dynorphin A (Dyn A) is an endogenous ligand for the opioid receptors with preference for the κ opioid receptor (KOR), and its structure-activity relationship (SAR) has been extensively studied at the KOR to develop selective potent agonists and antagonists. Numerous SAR studies have revealed that the Arg residue is essential for KOR activity. In contrast, our systematic SAR studies on [des-Arg]Dyn A analogues found that Arg is not a key residue and even deletion of the residue does not affect biological activities at the KOR. In addition, it was also found that [des-Arg]Dyn A(1-9)-NH is a minimum pharmacophore and its modification at the N-terminus leads to selective KOR antagonists. A lead ligand, 14, with high affinity and antagonist activity showed improved metabolic stability and could block antinociceptive effects of a KOR selective agonist, FE200665, in vivo, indicating high potential to treat KOR mediated disorders such as stress-induced relapse.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693303PMC
http://dx.doi.org/10.1021/acs.jmedchem.6b01411DOI Listing

Publication Analysis

Top Keywords

opioid receptor
8
sar studies
8
kor
7
structure-activity relationships
4
relationships [des-arg]dynorphin
4
[des-arg]dynorphin analogues
4
analogues opioid
4
receptor dynorphin
4
dynorphin dyn
4
dyn endogenous
4

Similar Publications

In this review, the primary aim is to examine non-azole ring systems that have analgesic activity and, where applicable, to establish structure - activity relationships (SARs) with the nine major pathways, prostaglandin synthesis inhibition, opioid receptor modulation, sodium channel blockade, enhancement of serotonin and norepinephrine levels, cannabinoid receptor (CBR) binding, N-methyl-D-aspartate (NMDA) receptor antagonism, transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonism, and P2X purinergic receptor blockade, have been described for pain relief. Analgesic effects have been observed in compounds containing ring systems such as piperidine, piperazine, pyridine, pyridazine, pyrazine, morpholine, thiomorpholine, pyran, thiopyran, indane, benzofuran, benzothiophene, quinoline, quinazoline, and chromene. These ring systems were classified in the whole study, first according to their molecular weights and then by bioisosteric similarity as same as first part.

View Article and Find Full Text PDF

Pharmacological modulation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) through dual GIP/GLP-1 receptor agonists, commonly used for diabetes and obesity, shows promise in reducing alcohol consumption. We applied drug-target Mendelian randomization (MR) using genetic variation at these loci to assess their long-term effects on problematic alcohol use (PAU), binge drinking, alcohol misuse classifications, liver health, and other substance use behaviors. Genetic proxies for lowered BMI, modeling the appetite-suppressing and weight-reducing effects of variants in both the GIPR and GLP1R loci ("GIPR/GLP1R"), were linked with reduced binge drinking in the primary (β = -0.

View Article and Find Full Text PDF

Ethnopharmacological Relevance: Chronic inflammatory pain represents a significant global health burden, seriously affecting the patient's quality of life. Jin-Tian-Ge Capsules (JTG), a substitute for natural tiger bone, has been approved in China for the treatment of osteoporosis, osteoarthritis and rheumatoid arthritis. Clinical observations show that JTG can mitigate chronic pain associated with the above bone-related diseases.

View Article and Find Full Text PDF

Background: Alcohol use disorder (AUD) is a pervasive problem in society afflicting millions of people worldwide. One reason for the prevalence of AUD is that heavy alcohol drinking can produce alcohol dependence. In addition, alcohol dependence dysregulates the body's stress systems to increase alcohol drinking.

View Article and Find Full Text PDF

The μ-opioid receptor (μOR) is the primary drug target of opioid analgesics such as morphine and fentanyl. Activation of μORs in the central nervous system inhibits ascending pain signaling to the cortex, thereby producing analgesic effects. However, the clinical use of opioid analgesics is severely limited by adverse side effects, including respiratory depression, constipation, addiction, and the development of tolerance.

View Article and Find Full Text PDF